Related Experiment Video
Updated: Feb 19, 2026
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
Serum microRNA expression profiling in patients with multiple system atrophy
Kodai Kume1, Hisakazu Iwama2, Kazushi Deguchi1
1Department of Neurology, Kagawa University Hospital, Kita‑gun, Kagawa 761‑0793, Japan.
Abstract:
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease that is pathologically characterized by α‑synuclein positive glial cytoplasmic inclusions in oligodendrocytes. The clinical diagnosis of MSA is often challenging as there are no established biomarkers and diagnoses are now based on clinical findings alone. At present, the etiology and pathogenesis of MSA are unclear. It has been reported that dysregulation of microRNA (miRNA/miR) serves an important role in neurodegenerative disorders including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. The miRNA profile of patients with MSA remains to be established. The present study investigated the serum miRNA expression level of 10 patients with MSA, using microarray chips including 668 miRNAs. It was identified that 50 miRNAs were significantly upregulated and 17 miRNAs were significantly downregulated in the serum of the patients with MSA. The most upregulated miRNA was miR‑16, which may induce the accumulation of α‑synuclein. The target genes of some miRNAs upregulated in MSA (including miR‑17, 20a, 24, 25, 30d and 451) were associated with autophagy‑associated molecules. The present study concluded that the expression pattern of miRNAs may be a clinical biomarker for MSA and targeting these miRNAs may provide a novel treatment for MSA.
Insights
Multiple system atrophy (MSA) research reveals distinct microRNA (miRNA) expression patterns in patient serum. These identified miRNA profiles show potential as diagnostic biomarkers and therapeutic targets for MSA.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Multiple system atrophy (MSA) is a rare neurodegenerative disease with challenging clinical diagnosis due to lack of biomarkers.
- Pathologically, MSA is defined by α‑synuclein inclusions in oligodendrocytes, but its etiology and pathogenesis remain unclear.
- MicroRNA (miRNA) dysregulation is implicated in other neurodegenerative disorders, suggesting a role in MSA.
Purpose of the Study:
- To investigate the serum miRNA expression profile in patients with Multiple system atrophy (MSA).
- To identify potential miRNA biomarkers for MSA diagnosis.
- To explore novel therapeutic strategies targeting miRNAs in MSA.
Main Methods:
- Serum samples from 10 MSA patients were analyzed using microarray chips covering 668 miRNAs.
- Quantitative analysis was performed to identify significantly upregulated and downregulated miRNAs.
Main Results:
- Significant alterations in serum miRNA levels were observed in MSA patients compared to controls.
- Fifty miRNAs were found to be significantly upregulated, and 17 were significantly downregulated.
- miR‑16 was the most upregulated miRNA, potentially linked to α‑synuclein accumulation. Several upregulated miRNAs target autophagy-associated molecules.
Conclusions:
- Serum miRNA expression patterns may serve as a valuable clinical biomarker for Multiple system atrophy (MSA).
- Targeting specific dysregulated miRNAs presents a potential novel therapeutic avenue for MSA treatment.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs